Patents by Inventor Alexey Lugovskoy

Alexey Lugovskoy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Anti-CD40 Ligand Antibodies
    Publication number: 20200223932
    Abstract: Anti-CD40L antibodies and antigen binding fragments thereof, compositions comprising the antibodies or antigen binding fragments, Anti-CD40L antibodies with reduced effector function, and method of using same for treatment of CD40L-related diseases or disorders.
    Type: Application
    Filed: May 23, 2018
    Publication date: July 16, 2020
    Inventor: Alexey Lugovskoy
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200157075
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: June 26, 2019
    Publication date: May 21, 2020
    Inventors: Bryce A. Harrison, Matthew G. Bursavich, Mark Brewer, Aleksey I. Gerasyuto, Kristopher N. Hahn, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200087299
    Abstract: Disclosed are small molecule inhibitors of av136 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: February 27, 2018
    Publication date: March 19, 2020
    Inventors: Mark Brewer, Matthew G. Bursavich, Aleksey I. Gerasyuto, Kristopher N. Hahn, Bryce A. Harrison, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • Bruton's tyrosine kinase inhibitors
    Patent number: 10577374
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 3, 2020
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20200002334
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: February 27, 2018
    Publication date: January 2, 2020
    Inventors: Bryce A. Harrison, Matthew G. Bursavich, Aleksey I. Gerasyuto, Kristopher N. Hahn, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20190365892
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 5, 2019
    Applicant: BIOGEN MA INC.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7)
    Publication number: 20190315692
    Abstract: Disclosed are small molecule antagonists of ?4?7 integrin, and methods of using them to treat a number of specific diseases or conditions.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventors: Matthew G. Bursavich, Dawn M. Troast, Bryce A. Harrison, Blaise S. Lippa, Bruce N. Rogers, Kyle D. Konze, Aleksey I. Gerasyuto, Tyler Day, Fu-Yang Lin, Kristopher N. Hahn, Mats A. Svensson, Byungchan Kim, Cheng Zhong, Alexey A. Lugovskoy, Brian Sosa
  • Anti-VLA-4 antibodies
    Patent number: 10335485
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 10072299
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 11, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
    Publication number: 20180244648
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Application
    Filed: February 27, 2018
    Publication date: August 30, 2018
    Inventors: Bryce A. Harrison, Matthew G. Bursavich, Mark Brewer, Aleksey I. Gerasyuto, Kristopher N. Hahn, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast
  • ANTI-VLA-4 ANTIBODIES
    Publication number: 20180221480
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: December 12, 2017
    Publication date: August 9, 2018
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • Substituted pyrimidines for inhibiting Raf kinase activity
    Patent number: 9920048
    Abstract: The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 20, 2018
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20180065974
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 8, 2018
    Inventors: Minna BUI, Patrick CONLON, Julio H. CUERVO, Daniel A. ERLANSON, Junfa FAN, Bing GUAN, Brian T. HOPKINS, Tracy J. JENKINS, Gnanasambandam KUMARAVEL, Alexey A. LUGOVSKOY, Doug MARCOTTE, Noel POWELL, Daniel SCOTT, Laura SILVIAN, Art TAVERAS, Deping WANG, Min ZHONG
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 9902999
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: February 27, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 9885087
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: February 6, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • Bruton's tyrosine kinase inhibitors
    Patent number: 9790229
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 17, 2017
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Protein A Binding Polypeptides, Anti-EphA2 Antibodies and Methods of Use Thereof
    Publication number: 20170267768
    Abstract: Provided by the present disclosure are antibodies (e.g., scFvs) that include CDRs and human framework regions that confer useful properties upon the antibodies. In certain embodiments, such properties include thermostability (e.g., increased melting temperature), efficient binding to Staphylococcus aureus Protein A, or both. In certain aspects, the antibodies are internalizing antibodies that specifically bind to the tumor associated antigen EphA2.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 21, 2017
    Inventors: James D. Marks, Daryl Drummond, Melissa Geddie, Dmitri Kirpotin, Neeraj Kohli, Alexey Lugovskoy
  • Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
    Patent number: 9738707
    Abstract: The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 22, 2017
    Assignee: Biogen MA Inc.
    Inventors: Frederick R. Taylor, Justin A. Caravella, Alexey A. Lugovskoy, Amna Saeed-Kothe, Ellen A. Garber
  • TANDEM FC BISPECIFIC ANTIBODIES
    Publication number: 20170218028
    Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.
    Type: Application
    Filed: December 9, 2016
    Publication date: August 3, 2017
    Inventors: Brian HARMS, Neeraj KOHLI, Alexey LUGOVSKOY, Stephen SU, Melissa GEDDIE
  • Methods for the detection of JC polyoma virus
    Patent number: 9696307
    Abstract: Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: July 4, 2017
    Assignee: Biogen MA Inc.
    Inventors: Leonid Gorelik, Alexey Lugovskoy